Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs) On-Demand Webinar Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs) Watch this on-demand webinar to learn how model-informed strategies using PopPK, PBPK, and QSP can…Certara2026 年 3 月 25 日
Why the most important Phase 3 decisions should be made before Phase 3 Blog Why the most important Phase 3 decisions should be made before Phase 3 Learn how advanced modeling for reimbursement strategy using MBMA and QSP strengthens payer evidence and…Certara2026 年 3 月 24 日
Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis Publication Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis This study evaluated the pharmacokinetics (PK) and pharmacokinetic–pharmacodynamic (PK–PD) relationship of clazakizumab, an anti–interleukin-6 (IL-6)…Danielle Pillsbury2026 年 3 月 24 日
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis Publication Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis This article describes how a model-informed drug development (MIDD) approach was used to support the…Certara2026 年 3 月 24 日
Regulatory horizons 2026: Clinical pharmacology strategy and regulatory expectations Blog Regulatory horizons 2026: Clinical pharmacology strategy and regulatory expectations Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…Certara2026 年 3 月 24 日
Building Trust in Data – Transparency, Traceability, and the Human Element Webinar Building Trust in Data – Transparency, Traceability, and the Human Element Danielle Pillsbury2026 年 3 月 5 日
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer Publication Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…Danielle Pillsbury2026 年 3 月 4 日
ADC first-in-human (FIH) dose selection: Designing FIH studies for success Blog ADC 首次人体(FIH)剂量选择:成功设计 FIH 研究的关键 Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…Certara2026 年 3 月 3 日
博客 Rare disease day 2026: Accelerating rare disease drug development through cross-functional innovation On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…Certara2026 年 2 月 26 日
From documentation to design: Building a scalable metadata strategy for clinical research Blog From documentation to design: Building a scalable metadata strategy for clinical research Learn how clinical teams are treating metadata as infrastructure to improve reuse, auditability, and standards…Certara2026 年 2 月 26 日